Conference Coverage
Latest News
Jun 22, 2026 | News
Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC
Unmet needs and emerging solutions in MRI-guided prostate cancer care
Jun 22, 2026
Retrospective study suggests differences in OAB therapy persistence among older adults
Jun 20, 2026
Sandip Prasad, MD, highlights 3-year data on mitomycin for intravesical solution for LG-IR-NMIBC
Jun 19, 2026
The UroOnc Minute: Keeping Patients Engaged in Active Surveillance, With Lourdes Guerrios-Rivera, MD, MSc
Jun 19, 2026
Advertisement
Shorts
0:36
EV-302 response rates put surgical consolidation in context
3 days ago
by
Betty Wang, MD
0:52
Amy E. Krambeck, MD, outlines anatomic enucleation course
4 days ago
by
Amy E. Krambeck, MD
1:23
Daniel J. George, MD, on the significance of capivasertib for PTEN-deficient mHSPC
5 days ago
by
Daniel J. George, MD
1:43
What it takes to move the needle on urologic patient safety
6 days ago
by
Matthew Nielsen, MD, MS, FACS
0:42
Why patients choose Break Wave over URS
7 days ago
by
Ben H. Chew, MD, MSc
0:36
Jenny N. Guo, MD, on key BPH takeaways from AUA 2026
11 days ago
by
Jenny N. Guo, MD
0:44
Joy Maulik, CRNP, highlights LUGPA Advanced Practice Provider Forum
12 days ago
by
Joy Maulik, CRNP
1:02
The UroOnc Minute: Patient selection for MDT in the PSMA-PET era
13 days ago
by
Adam B. Weiner, MD(+1 more)
0:55
Archan Khandekar, MD, on the future for AI in urology
14 days ago
by
Archan Khandekar, MD
0:45
Praful Ravi, MB, BChir, MRCP, on residual disease detection using PSMA-PET
17 days ago
by
Praful Ravi, MB, BChir, MRCP
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
The agency is requesting a removal of the limitation of use for age-related hypogonadism as well as updated warnings related to prostate cancer risk and benign prostatic hyperplasia.
Data from the RAMPART trial showed that durvalumab monotherapy missed the DFS threshold in resected RCC, though the combination with tremelimumab showed significant benefit.
Andrew J. Armstrong, MD, MSc, discusses efficacy results from a phase 2 study evaluating a chemoimmunotherapy regimen for patients with neuroendocrine or aggressive-variant metastatic prostate cancer.
The prospective RELIEF study will evaluate the safety and preliminary efficacy of IRE delivered via the NanoKnife System for BPH-related symptoms.
In this episode of Pearls & Perspectives, Thomas F. Stringer, MD, FACS, discusses his journey from private practice to academic urology, his priorities as incoming AUA president, and opportunities to improve men's health engagement and education.
The approval is supported by data from the phase 3 PIVOT-PO trial, in which tebipenem demonstrated noninferiority to imipenem-cilastatin.
Daniel J. George, MD, discusses the clinical significance of the FDA approval of capivasertib, practical considerations for PTEN testing and toxicity management, and the broader implications of precision medicine for patients with advanced prostate cancer.
Jenny Guo, MD, discusses data suggesting that hemi-HoLEP may be a viable treatment option for patients with prior pelvic radiation.
Daniel Eun, MD, discusses the future of reconstructive urology, highlighting the promise of telesurgery and AI-driven surgical technologies while emphasizing the practical barriers that must be addressed for widespread adoption.
Louise Emmett, MD, PhD, MBChB, FRACP, discusses findings from the phase 1 AcTION trial, which evaluated the safety and preliminary activity of 225Ac-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Advertisement
Toni K. Choueiri, MD, discusses the FDA approval of adjuvant belzutifan plus pembrolizumab for clear cell renal cell carcinoma, describing the regimen as a major advancement in kidney cancer treatment.
Patients who developed ototoxicity during cisplatin treatment experienced less worsening of pure-tone audiometry thresholds in ears treated with ACOU085 compared with placebo-treated ears.
Data from the BREEZE trial support the efficacy, safety, and tolerability of the Zenflow Prostatic Spring for BPH-related LUTS.
The approval is supported by data from the phase 3 CAPItello-281 trial.
The application is supported by data from the phase 3 LITESPARK-022 trial.
Advertisement
Advertisement
Trending on Urology Times
1
The ArteraAI Prostate Test: What It Is and How It Works
2
HHS requests testosterone therapy label updates, citing new safety data
3
Retrospective study suggests differences in OAB therapy persistence among older adults
4
Sandip Prasad, MD, highlights 3-year data on mitomycin for intravesical solution for LG-IR-NMIBC
5